Sonova downgraded to Underweight from Equal Weight at Morgan Stanley

Morgan Stanley analyst Robert Davies downgraded Sonova to Underweight from Equal Weight with a price target of CHF 270, down from CHF 310. The stock’s valuation has hit an all time high versus Demant and hearing aid peers, while the new product launch is known and currency is an increasing headwind, the analyst tells investors in a research note.